PATENTS

Evolution of CAR T-cell immunotherapy in terms of patenting activity

An analysis of published patent applications in chimeric antigen receptor (CAR) T-cell immunotherapy allows insight into the development of this emerging technology.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2: Geographical analysis of CAR T-cell patenting activity.
Fig. 3
Fig. 4: Patenting evolution of the top five CAR T-cell applicants.
Fig. 5: Network node map of CAR T-cell applicants.
Fig. 6: CAR T-cell patent value analysis.

Change history

  • 09 April 2019

    In the version of this article initially published online, the abstract read “dedvelopment” instead of “development” as a result of a publisher error. The error has been corrected in the print, PDF and HTML versions of this article.

References

  1. 1.

    Kolata, G. New gene-therapy treatments will carry whopping price tags. The New York Times https://www.nytimes.com/2017/09/11/health/cost-gene-therapy-drugs.html (11 September 2017).

  2. 2.

    Grady, D. Companies rush to develop ‘utterly transformative’ gene therapies. The New York Times https://www.nytimes.com/2017/07/23/health/gene-therapy-cancer.html (23 July 2017).

  3. 3.

    Sadelain, M. & Rivière, I. CAR T cells in cancer therapy (poster). Nat. Rev. Drug Disc. (December 2017).

  4. 4.

    Golstein, P. & Griffiths, G. M. Nat. Rev. Immunol. 18, 527–535 (2018).

    CAS  Article  Google Scholar 

  5. 5.

    Mullard, A. Nat. Rev. Drug Discov. 14, 301 (2015).

    Google Scholar 

  6. 6.

    Morrison, C. Nat. Biotechnol. 33, 571–572 (2015).

    CAS  Article  Google Scholar 

  7. 7.

    Dolgin, E. Nat. Biotechnol. 35, 891–892 (2017).

    CAS  Article  Google Scholar 

  8. 8.

    Trippe, A. Guidelines for Preparing Patent Landscape Reports (World Intellectual Property Organization, 2015).

  9. 9.

    Zuniga, P. et al. OECD Patent Statistics Manual (OECD, 2009).

  10. 10.

    European IPR Helpdesk. E-IPR fact sheet: automatic patent analysis. https://www.iprhelpdesk.eu/sites/default/files/newsdocuments/Fact-Sheet-Automatic-Patent-Analysis.pdf (2013).

  11. 11.

    Jürgens, B. & Herrero-Solana, V. J. Intell. Stud. Bus. 7, 17–26 (2017).

    Google Scholar 

  12. 12.

    Dara, A. & Sangamwar, A. T. PLoS One 9, e103847 (2014).

    Article  Google Scholar 

  13. 13.

    Pan, C. L. & Chen, F. C. Hum. Vaccin. Immunother. 13, 2583–2593 (2017).

    Article  Google Scholar 

  14. 14.

    Anaya, M., Perez-Santos, M. & Muñoz-Rojas, J. Intl. J. Cancer Biol. Clin. Oncol. 1, 14–18 (2017).

    Google Scholar 

  15. 15.

    Anonymous. Nat. Biotechnol. 35, 215 (2017).

    Article  Google Scholar 

  16. 16.

    Bouchie, A., Allison, M., Webb, S. & DeFrancesco, L. Nat. Biotechnol. 32, 229–238 (2014).

    CAS  Article  Google Scholar 

  17. 17.

    Bouchie, A. & DeFrancesco, L. Nat. Biotechnol. 33, 247–255 (2015).

    CAS  Article  Google Scholar 

  18. 18.

    Morrison, C. Nat. Biotechnol. 36, 131–136 (2018).

  19. 19.

    Yeager, A.J. CAR-T in the courts. Genetic Engineering News (11 September 2017).

Download references

Acknowledgements

This article is based on a study that was commissioned by the European Patent Office with the aim of demonstrating to readers outside the disciplines of patent analysis and CAR T-cell immunotherapy how patent information can be used to gain insight and competitive advantages about a specific technological field. The authors thank F. Aslund, P. Bumb and D. Manu from the European Patent Office for their support in the classification identification process and assistance for fine-tuning the search strategy. The opinions expressed in this article are those of the authors and not necessarily those of their employers.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Nigel S. Clarke.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Supplementary Information

Supplementary Methods

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jürgens, B., Clarke, N.S. Evolution of CAR T-cell immunotherapy in terms of patenting activity. Nat Biotechnol 37, 370–375 (2019). https://doi.org/10.1038/s41587-019-0083-5

Download citation

Further reading